Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 4 1Phase 3 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1

Interventions

Letrozole 5Tamoxifen 4Anastrozole 4ribociclib 3exemestane 3atezolizumab 3Vancomycin 3Nivolumab 3Magnetic Resonance Spectroscopy 3Injections 3Human Papillomavirus Recombinant Vaccine nonavalent 3Dexamethasone 3Carboplatin 3trametinib 2relatlimab 2pembrolizumab 2encorafenib 2dabrafenib 2binimetinib 2asciminib 2Specimen Handling 2Rituximab 2Prednisone 2Papillomavirus Vaccines 2Oxaliplatin 2Medroxyprogesterone Acetate 2Leucovorin 2Lenalidomide 2Ipilimumab 2Immune Checkpoint Inhibitors 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Zoledronic Acid × 90 days × Clear all
NCT04549207 2026-04-07

Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer

Ottawa Hospital Research Institute

Phase 4 Active not recruiting
240 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡